Document is current
Any future updates will be listed below
-
Authors
Patel, Rutulkumar https://orcid.org/0000-0001-6652-6070
Cooper, Daniel E.
Kadakia, Kushal T.
Allen, Annamarie
Duan, Likun
Luo, Lixia
Williams, Nerissa T.
Liu, Xiaojing https://orcid.org/0000-0002-4231-6017
Locasale, Jason W.
Kirsch, David G. https://orcid.org/0000-0002-2086-205X
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R35CA197616, T32CA093240, CA193256)
American Cancer Society (RSG-16-214-01-TBE)
American Association for Cancer Research (21-40-37-PATE)
- License Information
-
More Information
Article History
Received: 17 July 2023
Accepted: 29 April 2024
First Online: 20 May 2024
Competing interests
: D.G.K. is a co-founder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. D.G.K. is a member of the scientific advisory board and owns stock in Lumicell Inc, a company commercializing intraoperative imaging technology. None of these affiliations represents a conflict of interest with respect to the work described in this manuscript. D.G.K. is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. XRAD Therapeutics, Merck, Bristol Myers Squibb, and Varian Medical Systems provide research support to D.G.K., but this did not support the research described in this manuscript. J.W.L. advises Nanocare Technologies, Restoration Foodworks, and Cornerstone Pharmaceuticals, a company with interests in targeting cancer metabolism related to this work. The other authors have no conflicting interests.
